Positron emission tomography and molecular imaging of the prostate: An update

BJU International

Volumn 97, Issue 5, 2006, Pages 923-931

  Lawrentschuk, Nathan ^a,b,c   Davis, Ian D ^a,b   Bolton, Damien M ^a   Scott, Andrew M ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; CAPROMAB PENDETIDE IN 111; CARBACHOL; CARBON 11; CHOLINE FLUOROCHOLINE F 18; COLLOID TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; FLUOROTHYMIDINE F 18; J 591 ANTIBODY IN 111; J 591 ANTIBODY LU 177; J 591 ANTIBODY TC 99M; METHIONINE C 11; NITROGEN 13; OXYGEN 15; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DRUG ACCUMULATION; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG UPTAKE; HUMAN; IMMUNOSCINTIGRAPHY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; METASTASIS; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; RELIABILITY; SENTINEL LYMPH NODE; SHORT SURVEY; TISSUE DISTRIBUTION;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION;

EID: 33645731918     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06040.x     Document Type: Short Survey

References (41)

1. Brush JP. Positron emission tomography in urological malignancy. Curr Opin Urol 2001 11 175 9
2. Shreve PD Anzai Y Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging. physiologic and benign variants. Radiographics 1999 19 61 77
3. Sung J Espiritu JI Segall GM Terris MK. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 2003 92 24 7
4. Johns Putra L Lawrentschuk N Ballok Z et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004 64 1202 7
5. Barbieri A Monica B Sebastio N Incarbone GP Di Stefano C. [Value and limitations of transrectal ultrasonography and computer tomography in preoperative staging of prostate carcinoma]. Acta Biomed Ateneo Parmense 1997 68 23 6
6. Townsend DW Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002 75 S24 30
7. Bujenovic S. The role of positron emission tomography in radiation treatment planning. Semin Nucl Med 2004 34 293 9
8. Kwee SA Coel MN Lim J Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005 173 252 5
9. Picchio M Messa C Landoni C et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003 169 1337 40
10. Mathews D Oz OK. Positron emission tomography in prostate and renal cell carcinoma. Curr Opin Urol 2002 12 381 5
11. Effert PJ Bares R Handt S Wolff JM Bull U Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996 155 994 8
12. Oyama N Akino H Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001 22 963 9
13. Oyama N Akino H Suzuki Y et al. Prognostic value of 2-deoxy-2-[F-18] fluoro- d -glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002 4 99 104
14. Shreve PD Grossman HB Gross MD Wahl RL. Metastatic prostate cancer. initial findings of PET with 2-deoxy-2- [F-18]fluoro- d -glucose. Radiology 1996 199 751 6
15. Yang SN Liang JA Lin FJ Kao CH Lin CC Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002 128 325 8
16. Even-Sapir E Metser U Flusser G et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004 45 272 8
17. Ackerstaff E Pflug BR Nelson JB Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001 61 3599 603
18. Sutinen E Nurmi M Roivainen A et al. Kinetics of [(11) C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004 31 317 24
19. De Santis M Becherer A Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma. an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004 22 1034 9
20. Ramdave S Thomas GW Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001 166 825 30
21. Babaian RJ Murray JL Lamki LM et al. Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. J Urol 1987 137 439 43
22. Nargund V Al Hashmi D Kumar P et al. Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU Int 2005 95 1232 6
23. Hinkle GH Burgers JK Neal CE et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998 83 739 47
24. Sodee DB Malguria N Faulhaber P Resnick MI Albert J Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The Prostascint Imaging Centers. Urology 2000 56 988 93
25. Kahn D Williams RD Haseman MK Reed NL Miller SJ Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998 16 284 9
26. Murphy GP Maguire RT Rogers B et al. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997 33 281 5
27. Oyen WJ Witjes JA Corstens FH. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur Urol 2001 40 294 9
28. Jani AB Blend MJ Hamilton R et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med 2004 45 1315 22
29. Murphy GP Elgamal AA Troychak MJ Kenny GM. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 2000 42 315 7
30. Thomas CT Bradshaw PT Pollock BH et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003 21 1715 21
31. Schettino CJ Kramer EL Noz ME Taneja S Padmanabhan P Lepor H. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol 2004 183 519 24
32. Wilkinson S Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 2004 172 133 6
33. Ellis RJ Vertocnik A Kim E et al. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2003 57 362 70
34. Bander NH Trabulsi EJ Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003 170 1717 21
35. Vallabhajosula S Kuji I Hamacher KA et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005 46 634 41
36. Heidenreich A Ohlmann C Polyakov S. Anatomical extent of pelvic lymphadenectomy in bladder and prostate cancer. Eur Urol Suppl 2005 4 15 24
37. Bader P Burkhard FC Markwalder R Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003 169 849 54
38. Partin AW Kattan MW Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 1445 51
39. Wawroschek F Vogt H Weckermann D Wagner T Harzmann R. The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. Eur Urol 1999 36 595 600
40. Wawroschek F Vogt H Wengenmair H et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003 70 303 10
41. Weckermann D Wawroschek F Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005 47 45 51